Patents by Inventor Brian Hugh Ridgway
Brian Hugh Ridgway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8796294Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.Type: GrantFiled: June 4, 2012Date of Patent: August 5, 2014Assignee: Exelixis Patent Company LLCInventors: Suleyman Bahceci, William Bajjalieh, Jeff Chen, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, Byung Gyu Kim, James W. Leahy, Matthew Sangyup Lee, Gary L. Lewis, Morrison B. Mac, Grace Mann, Charles K. Marlowe, Brian Hugh Ridgway, Joan C. Sangalang, Xian Shi, Craig Stacy Takeuchi, Yong Wang
-
Patent number: 8754092Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.Type: GrantFiled: June 4, 2012Date of Patent: June 17, 2014Assignee: Exelixis Patent Company LLCInventors: Suleyman Bahceci, William Bajjalieh, Jeff Chen, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, Byung Gyu Kim, James W. Leahy, Matthew Sangyup Lee, Gary L. Lewis, Morrison B. Mac, Grace Mann, Charles K. Marlowe, Brian Hugh Ridgway, Joan C. Sangalang, Xian Shi, Craig Stacy Takeuchi, Yong Wang
-
4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use
Patent number: 8440663Abstract: This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R1, R2, R25, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: January 30, 2007Date of Patent: May 14, 2013Assignee: Exelixis, Inc.Inventors: Grace Mann, Naing Aay, Arlyn Arcalas, S. David Brown, Wai Ki Vicky Chan, Jeff Chen, Hongwang Du, Sergey Epshteyn, Timothy Patrick Forsyth, Adam A. Galan, Tai Phat Huynh, Mohamed Abdulkader Ibrahim, Henry William Beecroft Johnson, Brian Kane, Patrick Kearney, Byung Gyu Kim, Elena S. Koltun, James W. Leahy, Matthew Sangyup Lee, Gary L. Lewis, Lisa E. Meyr, Robin Tammie Noguchi, Michael Pack, Brian Hugh Ridgway, Xian Shi, John Woolfrey, Peiwen Zhou -
Publication number: 20120245139Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: EXELIXIS PATENT COMPANY LLCInventors: Suleyman Bahceci, William Bajjalieh, Jeff Chen, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, Byung Gyu Kim, James W. Leahy, Matthew Sangyup Lee, Gary L. Lewis, Morrison B. Mac, Grace Mann, Charles K. Marlowe, Brian Hugh Ridgway, Joan C. Sangalang, Xian Shi, Craig Stacy Takeuchi, Yong Wang
-
Publication number: 20120238570Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.Type: ApplicationFiled: June 4, 2012Publication date: September 20, 2012Applicant: EXELIXIS PATENT COMPANY LLCInventors: Suleyman Bahceci, William Bajjalieh, Jeff Chen, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, Byung Gyu Kim, James W. Leahy, Matthew Sangyup Lee, Gary L. Lewis, Morrison B. Mac, Grace Mann, Charles K. Marlowe, Brian Hugh Ridgway, Joan C. Sangalang, Xian Shi, Craig Stacy Takeuchi, Yong Wang
-
Patent number: 8222263Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.Type: GrantFiled: March 14, 2008Date of Patent: July 17, 2012Assignee: Exelixis Patent Company LLCInventors: Suleyman Bahceci, William Bajjalieh, Jeff Chen, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, Byung Gyu Kim, James W. Leahy, Matthew Sangyup Lee, Gary L. Lewis, Morrison B. Mac, Grace Mann, Charles K. Marlowe, Brian Hugh Ridgway, Joan C. Sangalang, Xian Shi, Craig Stacy Takeuchi, Yong Wang
-
Patent number: 8211929Abstract: The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, V is NR1R1a, or O—R1, wherein X is H, halo, C1-C6 alkyl, NO2, mono-, di-, or tri-halo substituted methyl, NR13R,14.Type: GrantFiled: December 28, 2005Date of Patent: July 3, 2012Assignee: Exelixis, Inc.Inventors: Jeff Chen, Lisa Esther Dalrymple Meyr, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, Mohamed Abdulkader Ibrahim, James W. Leahy, Gary Lee Lewis, Grace Mann, Larry W. Mann, Robin Tammie Noguchi, Brian Hugh Ridgway, Joan Cruz Sangalang, Kevin Luke Schnepp, Xian Shi, Craig Stacy Takeuchi, Matthew Alan Williams, John Nuss, Atwood K. Cheung
-
Patent number: 8178570Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.Type: GrantFiled: April 8, 2004Date of Patent: May 15, 2012Assignee: Exelixis, Inc.Inventors: Jeff Chen, Lisa Esther Dalrymple, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, James William Leahy, Brian Hugh Ridgway, Grace Mann, Larry W. Mann, Craig Stacy Takeuchi, Joan C. Sangalang
-
Patent number: 8088767Abstract: This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention.Type: GrantFiled: September 28, 2007Date of Patent: January 3, 2012Assignee: Exelixis, Inc.Inventors: Adam Antoni Galan, Jeff Chen, Hongwang Du, Timothy Forsyth, Tai Phat Huynh, Henry William Beecroft Johnson, Patrick Kearney, James W. Leahy, Matthew Sangyup Lee, Grace Mann, Brian Hugh Ridgway, Craig Stacy Takeuchi, Peiwen Zhou
-
Patent number: 8013156Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.Type: GrantFiled: March 19, 2004Date of Patent: September 6, 2011Assignee: Exelixis, Inc.Inventors: Lynne Canne Bannen, S. David Brown, Wei Cheng, Vasu Jammalamadaka, John M. Nuss, Morrison B. Mac, Jason Jevious Parks, Matthew A. Williams, Wei Xu, Atwood Kim Cheung, Lisa Esther Dalrymple, Sergey Epshteyn, Mohamed Abdulkader Ibrahim, James William Leahy, Gary Lee Lewis, Robin Tammie Noguchi, Larry Wayne Mann, Brian Hugh Ridgway, Joan C. Sangalang, Kevin Luke Schnepp, Xian Shi, Richard George Khoury
-
Publication number: 20110201599Abstract: A compound according to Formula I: or a pharmaceutically-acceptable salt thereof, wherein R1, R3, A, B and D are as defined in the specification; pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: July 2, 2009Publication date: August 18, 2011Applicant: EXELIXIS, INC.Inventors: Suleyman Bahceci, Bryan Chan, Diva Sze-Ming Chan, Jeff Chen, Timothy Patrick Forsyth, Maurizio Franzini, Vasu Jammalamadaka, Joon Won Jeong, Lisa Renee Jones, Ryan Michael Kelley, Moon Hwan Kim, James W. Leahy, Morrison B. Mac, Robin Tammie Noguchi, Pallavi Rao, Brian Hugh Ridgway, Wei Xu, Yong Wang
-
Publication number: 20100136136Abstract: This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention.Type: ApplicationFiled: September 28, 2007Publication date: June 3, 2010Applicant: EXELIXIS, INC.Inventors: Adam Antoni Galan, Jeff Chen, Hongwang Du, Timothy Forsyth, Tai Phat Huynh, Henry William Beecroft Johnson, Patrick Kearney, James W. Leahy, Matthew Sangyup Lee, Grace Mann, Brian Hugh Ridgway, Craig Stacy Takeuchi, Peiwen Zhou
-
Publication number: 20090298830Abstract: This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R1, R2, R25, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: January 30, 2007Publication date: December 3, 2009Applicant: Exelixis, Inc.Inventors: Grace Mann, Naing Aay, Arlyn Arcalas, S. David Brown, Wai Ki Vicky Chan, Jeff Chen, Hongwang Du, Sergey Epshteyn, Timothy Patrick Forsyth, Adam A. Galan, Tai Phat Huynh, Mohamed Abdulkader Ibrahim, Henry William Beecroft Johnson, Brian Kane, Patrick Kearney, Byung Gyu Kim, Elena S. Koltun, James W. Leahy, Matthew Sangyup Lee, Gary L. Lewis, Lisa E. Meyr, Robin Tammie Noguchi, Michael Pack, Brian Hugh Ridgway, Xian Shi, John Woolfrey, Peiwen Zhou
-
Publication number: 20090105211Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.Type: ApplicationFiled: March 14, 2008Publication date: April 23, 2009Applicant: Exelixis, Inc.Inventors: Suleyman Bahceci, William Bajjalieh, Jeff Chen, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, Byung Gyu Kim, James W. Leahy, Matthew Sangyup Lee, Gary L. Lewis, Morrison B. Mac, Grace Mann, Charles K. Marlowe, Brian Hugh Ridgway, Joan C. Sangalang, Xian Shi, Craig Stacy Takeuchi, Yong Wang
-
Publication number: 20080249079Abstract: The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, V is NR1R1a, or O—R1, wherein X is H, halo, C1-C6 alkyl, NO2, mono-, di-, or tri-halo substituted methyl, NR13R,14.Type: ApplicationFiled: December 28, 2005Publication date: October 9, 2008Applicant: EXELIXIS, INC.Inventors: Jeff Chen, Lisa Esther Dalrymple Meyr, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, Mohamed Abdulkader Ibrahim, James W. Leahy, Gary Lee Lewis, Grace Mann, Larry W. Mann, Robin Tammie Noguchi, Brian Hugh Ridgway, Joan Cruz Sangalang, Kevin Luke Schnepp, Xian Shi, Craig Stacy Takeuchi, Matthew Alan Williams, John Nuss, Atwood K. Cheung
-
Patent number: 7378427Abstract: Synthetic methods are provided for production of compounds of the formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are as defined in the specification.Type: GrantFiled: June 17, 2005Date of Patent: May 27, 2008Assignee: WyethInventors: Brian Hugh Ridgway, William Jay Moore, Mark Anthony Ashwell, William Ronald Solvibile, Amy Tsai-Ting Lee, Molly Elizabeth Hoke, Madelene Antane, Amedeo A. Failli
-
Patent number: 6894061Abstract: This invention provides a compound of formulae (I) or (II) having the structure or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.Type: GrantFiled: November 20, 2003Date of Patent: May 17, 2005Assignee: WyethInventors: Albert John Molinari, Mark Antony Ashwell, Brian Hugh Ridgway, Amedeo Arturo Failli, William Jay Moore
-
Publication number: 20040167155Abstract: This invention provides a compound of formulae (I) or (II) having the structure 1Type: ApplicationFiled: November 20, 2003Publication date: August 26, 2004Inventors: Albert John Molinari, Mark Antony Ashwell, Brian Hugh Ridgway, Amedeo Arturo Failli, William Jay Moore